Palatin Technologies has announced a partnership with telehealth service provider UpScriptHealth. The collaboration aims to raise awareness about hypoactive sexual desire disorder (HSDD) and increase the accessibility of Vyleesi through UpScriptHealth’s Women’s Health Platform.
According to the company Vyleesi is the only FDA-approved, as-needed treatment for acquired, generalized HSDD in premenopausal women. The partnership will make Vyleesi available to UpScriptHealth’s extensive patient base on their Women’s Telehealth Platform.
Since its inception in 2015, UpScriptHealth’s platform has provided women with efficient access to healthcare providers and therapies. The addition of Vyleesi reinforces the platform’s commitment to addressing women’s health issues, particularly HSDD.
Vyleesi is currently licensed in China to Fosun Pharma and in South Korea to Kwangdong Pharmaceuticals.
